Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.
Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder. One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause. Off-label, paroxetine may be used for the treatment of premature ejaculation or irritable bowel syndrome (IBS).
Research Site, Uppsala, Sweden
GSK Investigational Site, Uppsala, Sweden
VA Connecticut Healthcare Systems, West Haven, Connecticut, United States
Research Site, Uppsala, Sweden
Multiple Sclerosis Clinic, Health Sciences Centre, Winnipeg, Manitoba, Canada
GSK Investigational Site, Mexico, D.F., Mexico
VA Puget Sound Health Care System, Seattle, Seattle, Washington, United States
GSK Investigational Site
Medical University of South Carolina, Institute of Psychiatry, Charleston, South Carolina, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.